John Wilkins
Family Medicine · West Branch, MINPI 1689082539
Payments from drug & device makers
Across 129 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$264
- Lilly USA, LLC$261
- AstraZeneca$190
- Johnson & Johnson$174
- AbbVie$104
- Amgen$88
- plus $830 from 23 others
What the payments were for
- Food & beverage$1,88999%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $264 |
| Lilly USA, LLC | 26 | $261 |
| AstraZeneca | 14 | $190 |
| Johnson & Johnson | 10 | $174 |
| AbbVie | 6 | $104 |
| Amgen | 6 | $88 |
| GSK | 4 | $77 |
| Pfizer | 5 | $71 |
| Lundbeck LLC | 4 | $67 |
| Mylan Specialty L.p. | 4 | $61 |
| Novartis | 4 | $57 |
| Astellas Pharma US Inc | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 1 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Boehringer Ingelheim | 3 | $41 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Medtronic | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Smith+Nephew | 1 | $27 |
| Merck | 2 | $25 |
| Alkermes, Inc. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,911 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 862 | $415,015 |
| TrulicityDulaglutide | 291 | $249,241 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 220 | $246,409 |
| JardianceEmpagliflozin | 226 | $169,032 |
| FarxigaDapagliflozin Propanediol | 290 | $162,193 |
| IngrezzaValbenazine Tosylate | 27 | $150,906 |
| OzempicSemaglutide | 81 | $122,289 |
| XareltoRivaroxaban | 109 | $98,186 |
| InvokanaCanagliflozin | 93 | $75,085 |
| RybelsusSemaglutide | 41 | $61,213 |
| JanuviaSitagliptin Phosphate | 85 | $59,853 |
| MounjaroTirzepatide | 54 | $53,073 |
| Dupixent SyringeDupilumab | 13 | $46,730 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $33,019 |
| MyrbetriqMirabegron | 49 | $30,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $71 | $415,015862 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $261 | $302,314345 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $77 | $291,537309 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $41 | $197,870287 claims |
| Novo NordiskOzempic, Rybelsus | $264 | $183,502122 claims |
| Johnson & JohnsonXarelto, Invokana | $174 | $173,271202 claims |
| AstraZenecaFarxiga | $190 | $162,193290 claims |
| MerckJanuvia | $25 | $59,85385 claims |
| AbbVieVraylar, Linzess | $104 | $31,32937 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $30,43249 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $29 | $28,31918 claims |
| Sanofi-aventis U.S. LLCMultaq | $40 | $16,78718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in West Branch
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.